Miravant Starts Photodynamic Therapy Trial for Psoriasis
SANTA BARBARA, Calif., Jan. 11 -- Miravant Medical Technologies has begun treating patients in a phase II clinical trial of PhotoPoint photodynamic therapy (PDT) for plaque psoriasis, a chronic skin disease in which the immune system triggers accelerated growth of skin cells. The clinical trial is an open-label, drug and light dose-ranging study to assess the safety and efficacy of single topical PhotoPoint treatments. The study targets 54 patients with moderate plaque-type psoriasis who will be treated at various dermatology centers and followed for up to 12 weeks.
PhotoPoint PDT uses Miravant's proprietary light-activated topical drug MV9411 to locally treat psoriatic plaques, abnormal skin lesions that can cause patients discomfort or pain.
In the two-step investigational procedure, varying doses of PhotoPoint MV9411 are applied directly to psoriatic plaques, followed by a light treatment. This proprietary drug completed a phase I drug-only safety study with healthy volunteers in 2001.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024